Group Urges Easier Access to Plasma Neuropathy Therapies

A new white paper from the Neuropathy Action Foundation identifies outdated state rules, supply strains and insurance barriers limiting patient access.

Updated on Nov. 17, 2026 in Diabetes

Rows of clear unlabeled plasma bags filled with pale golden liquid hang on steel rails in a cool, clean storage room, illustrating the supply of plasma-derived therapies.
The Neuropathy Action Foundation urged federal and state action on outdated plasma collection rules, supply constraints and insurance denials that delay care for millions of Americans. AI Illustration. Upload story photo >

Live Poll

Do you trust your health insurer to approve treatments you need without unnecessary delays?

The Neuropathy Action Foundation released a white paper on improving access to plasma-derived therapies for neuropathy, developed with M2 Health Care Consulting. The paper points to outdated state regulations, plasma supply challenges and insurance restrictions as barriers for patients.

Why it matters

More than 20 million Americans live with some form of neuropathy, and many depend on plasma-derived treatments that can be hard to obtain. Easing these barriers could affect how quickly patients receive prescribed care across the United States.

The white paper cites more than 20 million Americans living with some form of neuropathy and says the United States supplies over 70 percent of the world's plasma, with finished medicines taking up to a year to manufacture. It does not estimate how many patients would gain access if the identified barriers were removed.

The players

Neuropathy Action Foundation

A nonprofit organization focused on neuropathy patients that issued the white paper on plasma-derived therapy access.

M2 Health Care Consulting

A health care consulting firm that partnered with the Neuropathy Action Foundation to develop the white paper.

The details

The white paper covers the full plasma supply system, from healthy human donors through manufacturing of finished medicines. It identifies outdated state regulations for source-plasma collection, plasma supply challenges, and insurance restrictions, including denials and repeated prior authorization requirements, as obstacles to patients receiving therapy. California Assembly Bill 2009 and Connecticut Senate Bill 368 are cited as recent efforts to modernize state rules for plasma collection.

Timeline

  1. November 17, 2026: Neuropathy Action Foundation releases the white paper.

Policy Context

The white paper points to California Assembly Bill 2009 and Connecticut Senate Bill 368 as recent state efforts to modernize source-plasma collection rules. It frames its recommendations as a continuation of that work, aimed at the regulatory gaps that remain.

Patients who rely on plasma-derived treatments may face insurance denials and repeated prior authorization requests before receiving prescribed therapy. The white paper's recommendations focus on reducing these delays in how care is approved and delivered.

The takeaway

Patients facing neuropathy who are denied prescribed plasma-derived therapy can ask their insurer for the specific reason in writing and request a formal appeal. Understanding these access barriers may help patients prepare for the prior authorization process.

Further reading

Explore more on Diabetes, a condition closely linked to many forms of neuropathy.

More information

Read the full white paper from Neuropathy Action Foundation.

Live Poll

Do you trust your health insurer to approve treatments you need without unnecessary delays?